05/25/23 5:00 PMNasdaq : DCPH conferencesclinical trialDeciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual MeetingDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced four poster presentations at the upcoming 2023 American Society of Clinical Oncology Annual Meeting, being held in Chicago, Illinois on June 2-6, 2023..RHEA-AIneutral
05/23/23 7:00 AMNasdaq : DCPH conferencesDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:. TD Cowen 4th Annual Oncology Innovation...RHEA-AIneutral
05/08/23 7:00 AMNasdaq : DCPH conferencesDeciphera Pharmaceuticals to Present at the JMP Securities Life Sciences ConferenceDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 2:30 PM ET...RHEA-AIneutral
05/03/23 7:00 AMNasdaq : DCPH earningsDeciphera Pharmaceuticals Announces First Quarter 2023 Financial ResultsDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. Recorded $33.2 million in QINLOCK net product revenue in the...RHEA-AIneutral
04/26/23 7:00 AMNasdaq : DCPH earningsDeciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023. In connection with the earnings release, Deciphera’ s management team...RHEA-AIneutral
04/19/23 7:00 AMNasdaq : DCPH conferencesDeciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology DaysDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on Wednesday, April 26, 2023 at...RHEA-AIneutral
03/14/23 5:53 PMNasdaq : DCPH Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that QINLOCK ® has been included in the latest National Comprehensive Cancer Network ® Clinical Practice Guidelines in Oncology as a preferred...RHEA-AIpositive
03/14/23 5:32 PMNasdaq : DCPH Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023. Poster Number: 4872 Title:...RHEA-AIneutral
03/01/23 7:00 AMNasdaq : DCPH clinical trialDeciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCTDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the completion of enrollment in the pivotal Phase 3 MOTION study of vimseltinib in patients with tenosynovial giant cell tumor not amenable to surgery.RHEA-AIneutral
02/27/23 7:00 AMNasdaq : DCPH conferencesDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:. Cowen 43rd Annual Health Care Conference...RHEA-AIneutral